Abstracts tagged "autoantibodies"

Abstract Number: 787 • 2018 ACR/ARHP Annual Meeting
Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?
Maaike Boonstra¹, Maarten K. Ninaber², Nina Ajmone Marsan³, Hans U. Scherer¹, Tom W.J. Huizinga¹ and Jeska de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Heart and Lung Center; Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ³Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: SSc is known for its heterogeneous disease course in which anti-topoisomerase I antibodies (ATA) are associated with dcSSc and interstitial lung disease and therefore…
Abstract Number: 1350 • 2018 ACR/ARHP Annual Meeting
Elevated Serum Levels of Soluble CD146 and CD146 Autoantibody in Patients with Polymyositis/Dermatomyositis
Eri Watanabe¹, Takahisa Gono^1,2, Hiroki Yabe¹, Masataka Kuwana², Kazunori Kato³ and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Biomedical Engineering, Faculty of Science and Engineering, Toyo University, Saitama, Japan
Background/Purpose: CD146 is a transmembrane glycoprotein belong to immunoglobulin superfamily, acts as adhesion molecule for the maintenance of cell monolayer. Human endothelial cells constitutively express…
Abstract Number: 2087 • 2018 ACR/ARHP Annual Meeting
Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance
Sladjana Skopelja-Gardner¹, YuFeng Peng², Payton Hermanson², Lucrezia Colonna², Xizhang Sun³, Lena Tanaka⁴, Anne Davidson⁵, David Salant⁶ and Keith B. Elkon⁷, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA, ⁴Medicine/Rheumatology, University of Washington, Seattle, WA, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Boston University, Boston, MA, ⁷University of Washington, Seattle, WA
Background/Purpose: Lupus nephritis (LN) affects ~70% of systemic lupus erythematosus (SLE) patients and is one of the main contributors to morbidity and mortality. While defective…
Abstract Number: 793 • 2018 ACR/ARHP Annual Meeting
Clinical Associations of Anti-U11/U12 (RNPC-3) Autoantibodies in Patients with Systemic Sclerosis
Lorenzo Beretta¹, Michael Mahler², Chelsea Bentow², Andrea Seaman², Fabrece Roup², Michelle Amio², Karl Norvell², Jay Milo², Susan Encabo², Janire Perurena³, Maite Sanz³, Alfredo Guillen⁴, Ana Marín³, Vicent Fonollosa³, Eduardo Callejas³ and Carmen Pilar Simeón⁴, ¹Scleroderma Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Scleroderma Unit, Internal Medicine Department, Vall d’Hebron Hospital, Barcelona, Spain, ⁴Scleroderma Unit, Internal Medicine Department, Vall d’Hebron Hospital, Barcelona, Spain
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…
Abstract Number: 1463 • 2018 ACR/ARHP Annual Meeting
Do Anti-Citrullinated Protein Antibodies and Anti-Sjögren’s-Syndrome-Related Antigen a Double Positive Patients with Secondary Sjögren’s Syndrome and RA Have Higher Joint Disease Activity?
Evo Alemao¹, Yogesh Saini², Ying Bao¹, Aarti Rao², Christine K Iannaccone³, Michelle Frits³, Michael E Weinblatt³ and Nancy A. Shadick³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is considered an extra-articular manifestation of RA and is an autoantibody-mediated condition similar to RA. Thus, patients (pts) with sSS…
Abstract Number: 2088 • 2018 ACR/ARHP Annual Meeting
Human TLR8 at the Interface between Innate and Adaptive Immunity in Systemic Lupus Erythematosus
Naomi I. Maria¹, Megan Woods², Shani Martinez¹, Chirag Raparia², Weiqing Huang² and Anne Davidson², ¹Center for Autoimmunnity, Musculoskeletal & Hematopoietic Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²Center for Autoimmunity, Musculoskeletal & Hematopoietic Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Infiltrating macrophages are one of the hallmarks of renal inflammation and kidney damage in lupus nephritis (LN). Surprisingly overexpression of TLR8, but not other…
Abstract Number: 794 • 2018 ACR/ARHP Annual Meeting
Identification of an Immunodominant Epitope on Rnpc-3 As a Target of Autoantibodies in Patients with Systemic Sclerosis
Michael Mahler¹, Chelsea Bentow¹, Jay Milo¹, Marie Hudson^2,3, Murray Baron³, May Choi⁴ and Marvin J. Fritzler⁴, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²Division of Rheumatology, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada, ³Department of Medicine, McGill University, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…
Abstract Number: 1469 • 2018 ACR/ARHP Annual Meeting
Measurement of Anti-Amyloid β Autoantibodies in Patients with Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Tomohisa Tani³ and Toshiro Ohashi³, ¹R, Ohashi-Tani Orthopaedic, Gifu, Japan, ²Advanced Diagnostic System Research Laboratory, Fujita Health University, Toyoake, Japan, ³Ohashi-Tani Orthopaedic, Gifu, Japan
Background/Purpose: Amyloid β (Aβ) accumulation in the brain is a risk factor for Alzheimer's disease (AD). The incidence of AD increases with age. Rheumatoid arthritis…
Abstract Number: 2096 • 2018 ACR/ARHP Annual Meeting
Ectonucleotidase CD73 Suppresses Autoantibody Production and Arterial Vasculopathy in Murine Lupus
Ramadan A. Ali¹, Nicole R. Pearce¹, Srilakshmi Yalavarthi¹, Kevin B. Atkins¹, Alex A. Gandhi¹, Yogendra Kanthi¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: CD73 is a surface nucleotidase that extends into the extracellular space where it generates adenosine from AMP. By regulating a cell’s “purinergic halo,” CD73…
Abstract Number: 4 • 2018 ACR/ARHP Annual Meeting
Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Susanne Graslund^1,2,3, Roman Zubarev⁴, Ingrid E. Lundberg^1,2 and Susanna L. Lundström⁴, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry I, Stockholm, Sweden
Background/Purpose: IgG Fc-glycans affect IgG function and are altered in autoimmune diseases and autoantibodies. Anti-histidyl tRNA synthetase autoantibodies (anti-Jo1) are frequent in myositis associated with…
Abstract Number: 796 • 2018 ACR/ARHP Annual Meeting
Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis
Wanlong Wu^1,2, Petra Hoederath¹, Eric Hachulla³, Paolo Airò⁴, Gabriele Valentini⁵, Marco Matucci Cerinic⁶, Franco Cozzi⁷, Gabriela Riemekasten⁸, Yannick Allanore⁹, Patricia Carreira¹⁰, Suzana Jordan¹¹ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ³Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, ⁴Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁵Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁶Division of Rheumatology, Division of Rheumatology, University of Florence, Florence, Italy, ⁷Division of Rheumatology, Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ⁹Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ¹⁰Servicio de Reumatologia, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Anti-U1RNP antibodies can be detected in patients with systemic sclerosis (SSc). However, their prevalence and clinical correlation with organ-specific complications have not been well…
Abstract Number: 1471 • 2018 ACR/ARHP Annual Meeting
ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients
Natalia Regine de Franca Shimabukuro^1,2, Maximilien Lora¹, Mariana Useche³, Zhijie Zhou⁴, Joyce Rauch⁵, Luis Eduardo Coelho Andrade², Henri Menard¹ and Ines Colmegna⁶, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Federal University of São Paulo, São Paulo, Brazil, ³Medicine, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Aurora Medical Centre, Oshkosh, WI, ⁵Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁶The Research Institute of the McGill University Health Centre, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada
Background/Purpose: Anti-citrullinated protein/peptide autoantibodies (ACPAs) define a major subset of rheumatoid arthritis (RA) patients. Cyclic citrullinated peptides (CCP) are commonly used as the antigen for…
Abstract Number: 2124 • 2018 ACR/ARHP Annual Meeting
Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Ryan Pachucki¹, Chelsea Corradetti², Stefania Gallucci³, Cagla Tukel³, Sarah Tursi³, Laura Nicastro³, Lynne Kohler², Yaj Ghadiali⁴, Laurie Kilpatrick⁵ and Roberto Caricchio¹, ¹Medicine Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, ²Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, ³Microbiology and Immunology, Lewis Katz School of Medicine, Philadelphia, PA, ⁴Medicine, Lewis Katz School of Medicine, Philadelphia, PA, ⁵Temple Lung Center, Lewis Katz School of Medicine, Philadelphia, PA
Background/Purpose: Infections are a major contributor to lupus disease. We have previously demonstrated that bacterial amyloid curli, produced by E.coli, can accelerate disease in mouse…
Abstract Number: 6 • 2018 ACR/ARHP Annual Meeting
Ro52/Trim21 Influences Follicular B Cell Homeostasis and Immunoglobulin Production
Margarita Ivanchenko¹, Susanna Brauner², Gudny Ella Thorlacius¹, Aurélie Ambrosi¹ and Marie Wahren-Herlenius¹, ¹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Neuroimmunology Unit, Department of Clinical Neurosciences, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Solna, Sweden
Background/Purpose: Systemic rheumatic diseases are characterized by abnormal B cell activation with autoantibody production and hypergammaglobulinemia. The autoantigen Ro52/SSA, also denoted TRIM21, is a major…
Abstract Number: 805 • 2018 ACR/ARHP Annual Meeting
Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival
Alicia M. Hinze^1,2, Laura K. Hummers¹, Fredrick M. Wigley¹, Monica Mukherjee³ and Ami A. Shah¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma heart disease often goes unrecognized until severe clinical manifestations are present. Diastolic dysfunction (DD) may identify patients at risk for cardiac complications by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].